Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Halozyme ( (HALO) ).
On April 30, 2026, Halozyme Therapeutics announced the appointment of veteran Johnson & Johnson finance executive Darren Snellgrove as its new chief financial officer, effective June 8, 2026, with interim CFO David Ramsay shifting to an advisory role for a brief transition. Snellgrove, who previously served as CFO of J&J’s pharmaceuticals business and led its investor relations function, will oversee Halozyme’s financial strategy, capital allocation, corporate development and investor relations, reinforcing the company’s push to leverage its expanding drug delivery technologies and royalty streams to drive long‑term growth and shareholder value.
Halozyme has structured a highly competitive pay package to secure Snellgrove after nearly three decades at J&J, including a $670,000 base salary, incentive bonus eligibility, a minimum $4 million long‑term incentive award starting in 2027 and $7.2 million in initial equity grants split between restricted stock units and stock options. The mix of make‑whole RSUs, performance‑tied options and a $350,000 sign‑on cash bonus underscores Halozyme’s reliance on experienced financial leadership to support its growing network of global pharma partnerships and to manage an increasingly complex, innovation‑driven business model.
The most recent analyst rating on (HALO) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
The score is driven primarily by strong financial performance—especially excellent free-cash-flow generation and high-margin, growing royalties—supported by upbeat 2026 guidance. This is meaningfully tempered by weak technicals (below major moving averages with negative MACD) and balance-sheet/capital-structure concerns (thin equity base and prior leverage), while valuation appears reasonable but not clearly discounted.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. is a San Diego‑based biopharmaceutical company focused on drug delivery technologies and drug‑device combination products that improve the subcutaneous administration of biologics and other therapies. Its flagship ENHANZE drug delivery platform, based on the proprietary rHuPH20 enzyme, underpins partnered products with major pharmaceutical companies and supports a portfolio that includes Hypercon and Surf Bio hyperconcentration technologies, as well as proprietary products Hylenex and XYOSTED sold across more than 100 global markets.
Average Trading Volume: 1,726,585
Technical Sentiment Signal: Buy
Current Market Cap: $7.47B
Find detailed analytics on HALO stock on TipRanks’ Stock Analysis page.